Toll-Like Receptor 8 Agonist - Pipeline Insight, 2024

This “Toll-Like Receptor 8 Agonist- Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Toll-Like Receptor 8 Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Toll-Like Receptor 8 Agonist: Understanding

Toll-Like Receptor 8 Agonist: Overview

Toll-like receptor 8, also known as TLR7, is a protein that in humans is encoded by the TLR7 gene. Orthologs are found in mammals and birds. It is a member of the toll-like receptor (TLR) family and detects single stranded RNA. A toll-like receptor type 7 and 8 (TLR7/8) agonist with potential immunostimulating and antitumor activities. Upon intratumoral administration, TLR7/8 agonist MEDI9197 binds to and activates TLR7 and 8, thereby stimulating antigen-presenting cells (APCs), including dendritic cells (DCs). Activation of DCs results in the production of proinflammatory cytokines, and the activation of cytotoxic T-lymphocyte (CTL) and B-lymphocyte immune responses. This may cause tumor cell lysis. TLR7 and 8, members of the TLR family, play fundamental roles in the activation of the immune system.

A typical TLR is a single-spanning receptor consisting of three domains: an extracellular domain (ECD) for the recognition of pathogen-associated molecular patterns (PAMPs), a transmembrane domain (TMD), and an intracellular Toll-interleukin 1 receptor (TIR) domain for initiating downstream signaling.

TLR8 agonists stimulate NK cell activity, enhance antibody-dependent cytotoxicity, and induce the production of IFN-?. TLR8 signaling mainly results in NF-kB pathway activation and subsequent proinflammatory cytokines and chemokines expression. Compared with TLR7 and TLR9, TLR8 is more widely distributed in immune cell subsets, and selective agonists can effectively activate mDC and monocytes. TLR8 activated mDC is very suitable for producing an acquired immune response against tumor cells. Activated mDCs phagocytize apoptotic and necrotic tumor cells and effectively cross-present tumor-associated antigens to CD8+ CTL.

Toll-Like Receptor 8 Agonist- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Toll-Like Receptor 8 Agonist pipeline landscape is provided which includes the disease overview and Toll-Like Receptor 8 Agonist treatment guidelines. The assessment part of the report embraces, in depth Toll-Like Receptor 8 Agonist commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Toll-Like Receptor 8 Agonist collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Toll-Like Receptor 8 Agonist R&D. The therapies under development are focused on novel approaches to treat/improve Toll-Like Receptor 8 Agonist.

Toll-Like Receptor 8 Agonist Emerging Drugs Chapters

This segment of the Toll-Like Receptor 8 Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Toll-Like Receptor 8 Agonist Emerging Drugs

EIK 1001: Eikon therapeuticsEIK1001 is a systemically-administered agonist of toll-like receptors 7 and 8. The compound has demonstrated single-agent activity as well as activity in combination with anti-PD-(L) 1 agents across multiple solid tumor types in Phase 1 trials. Currently, the drug is in Phase II stage of its development for the treatment of NSCLC.

TransCon TLR7/8 Agonist: Ascendis PharmaTransCon TLR7/8 Agonist is an investigational long-acting prodrug of resiquimod, a small molecule agonist of Toll-like receptors (TLR) 7 and 8 designed to provide sustained activation of intratumoral antigen-presenting cells driving tumor antigen presentation and induction of immune stimulatory cytokines for weeks or months with a single intratumoral injection. Currently, the drug is in Phase II stage of its development for the treatment of Head and Neck Neoplasms.

Toll-Like Receptor 8 Agonist: Therapeutic Assessment

This segment of the report provides insights about the different Toll-Like Receptor 8 Agonist drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Toll-Like Receptor 8 Agonist

• There are approx. 10+ key companies which are developing the therapies for Toll-Like Receptor 8 Agonist. The companies which have their Toll-Like Receptor 8 Agonist drug candidates in the most advanced stage, i.e. phase III include, Eikon therapeutics.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Toll-Like Receptor 8 Agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Toll-Like Receptor 8 Agonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Toll-Like Receptor 8 Agonist therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Toll-Like Receptor 8 Agonist drugs.

Toll-Like Receptor 8 Agonist Report Insights

• Toll-Like Receptor 8 Agonist Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Toll-Like Receptor 8 Agonist Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Toll-Like Receptor 8 Agonist drugs?
• How many Toll-Like Receptor 8 Agonist drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Toll-Like Receptor 8 Agonist?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Toll-Like Receptor 8 Agonist therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Toll-Like Receptor 8 Agonist and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Eikon therapeutics
• Ascendis Pharma
• Cello Therapeutics
• Gilead Sciences

Key Products

• EIK 1001
• TransCon TLR7/8 Agonist
• Platelet membrane coated resiquimod nanoparticles
• Selgantolimod

This product will be delivered within 2 business days.